Wedbush analyst David Nierengarten raised the firm's price target on Artiva Biotherapeutics to $40 from $23 and keeps an Outperform rating on the shares. First results for AlloNK plus rituximab in refractory rheumatoid arthritis met a "best case" upside scenario, with six-month efficacy surpassing a target threshold of 50% of patients achieving ACR50 response, no loss of response in any treatment subjects, and a safety profile supporting outpatient administration, the firm notes.
